---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-276477"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:26:07.172854+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Magenta Therapeutics Q3 net loss $16.1M; cash $128.3M funds into Q2 2024

## Summary
- Cash, equivalents and marketable securities $128.3M at Sept 30, 2022, down from $176.9M at Dec 31, 2021.
- Net loss of $16.1M for Q3 2022 vs $17.4M in Q3 2021; R&D expense $11.2M, G&A $6.1M.
- MGTA-117 Phase 1/2 trial in AML/MDS progressing; no related SAEs or DLTs; Cohort 3 enrollment completed.
- CD45-ADC toxicology study done; IND-enabling ongoing; program update expected Dec 2022.
- MGTA-145 sickle cell trial enrolling; initial data anticipated Dec 2022, comprehensive data H1 2023.

## SEC filing metadata
- accession: 0001193125-22-276477
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312522276477/0001193125-22-276477-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312522276477/d349418d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-276477
- JSON: https://secwatch.observer/filing/0001193125-22-276477.json
- Plain text: https://secwatch.observer/filing/0001193125-22-276477.txt

## Key facts
- Earnings Releases
  Dianthus Therapeutics, Inc. /DE/ reported financial results for third quarter ending September 30, 2022.
  - Period: third quarter ending September 30, 2022
  - Result: reported results
  source text: Magenta Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312522276477/0001193125-22-276477-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.